Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes
March 19th 2025The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading dose of a minimum of three monthly intravitreal aflibercept injections that was followed by a TAE.
Stealth BioTherapeutics reaches 50 percent enrollment target in phase 3 ReNEW study
March 17th 2025The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide, a first-in-class mitochondria-targeted investigational therapeutic.
ARVO announces Swathi Kaliki, MD, as recipient of 2025 Ludwig von Sallmann Clinician-Scientist Award
March 15th 2025The award honors Ludwig von Sallmann, MD, a “distinguished international ophthalmologist and ophthalmic investigator whose contributions greatly increased the basic and clinical understanding of vision and ophthalmology.”
Survey reveals gaps in patient awareness of preservative-free glaucoma treatments
March 14th 2025A survey conducted by the Preservative Freedom Coalition, asked 558 patients with glaucoma or ocular hypertension how they felt about their treatments, the future of their eye health, trust in their doctors and more.